glp-1 drugs and autoimmune disease Obesity May Lower Risk of Heart for People With Disease The Thyroid Twist: How GLP-1

82:395-405 [PMC free article: PMC11822619] [PubMed: 39937469] 349

Statements Data availability statement The original contributions presented in the study are included in the article/ Supplementary Materials , further inquiries can be directed to the corresponding author/s

Serious risks identified in FDA labeling: FDA labeling for approved GLP-1 and GLP-1/GIP medications includes warnings about risk of pancreatitis, gallbladder disease, acute kidney injury (often related to dehydration from severe gastrointestinal effects), hypoglycemia (particularly when combined with insulin or sulfonylureas), diabetic retinopathy complications in patients with type 2 diabetes, and serious hypersensitivity reactions

(2008) discovered a fascinating correlation, whereby GLP-2 exhibited a reduction in PTH levels among the control individuals possessing an intact intestinal system, thus establishing PTH as a plausible mediator of the GLP-2-induced decline in CTX-

This support system fosters accountability and encourages long-term adherence to treatment plans